Worth Watching Stocks: Celsion Corp. (NASDAQ:CLSN), Potash Corporation of Saskatchewan Inc. (NYSE:POT), Bristol-Myers Squibb Company (NYSE:BMY), Rite Aid (NYSE:RAD), Inovio Pharmaceuticals(NASDAQ:INO)

Celsion Corp. (NASDAQ:CLSN) shares increased 3.45% in last trading session and ended the day at $2.40. CLSN return on assets is -38.80%. Celsion Corp. (NASDAQ:CLSN) quarterly performance is -9.68%. On 13 July, Celsion Corp. (NASDAQ:CLSN) said that, it provides an overview of the Celsion Corporation’s pharmaceutical research and development focus.

Potash Corporation of Saskatchewan Inc. (NYSE:POT) belongs to Basic Materials sector. Its net profit margin is 22.10% and weekly performance is -2.08%. On last trading day company shares ended up $29.18. Potash Corporation of Saskatchewan Inc. (NYSE:POT) distance from 50-day simple moving average (SMA50) is -5.73%. Potash Corporation of Saskatchewan Inc. (NYSE:POT) announced that its Board of Directors has declared a quarterly dividend of US $0.38 per share payable July 31, 2015 to shareholders of record July 10, 2015.

Bristol-Myers Squibb Company (NYSE:BMY) shares moved up 0.57% in last trading session and ended the day at $70.06. BMY Gross Margin is 77.20% and its return on assets is 6.70%. Bristol-Myers Squibb Company (NYSE:BMY) quarterly performance is 10.03%. Bristol-Myers Squibb Company (NYSE:BMY) had its price objective hosited by Jefferies Group from $66.00 to $67.00 in a report released on Monday. Jefferies Group currently has a hold rating on the biopharmaceutical company’s stock.

On 14 July, Rite Aid Corporation (NYSE:RAD) shares moved down -0.79% and was closed at $8.82. RAD EPS growth in last 5 year was 40.80%. Rite Aid Corporation (NYSE:RAD) year to date (YTD) performance is 17.29%. On 2 July, Rite Aid Corporation (NYSE:RAD) announced sales results for June. For the four weeks ended June 27, 2015, same store sales increased 2.4 percent over the prior-year period. June front-end same store sales increased 0.3 percent. Pharmacy same store sales, which included an approximate 226 basis points negative impact from new generic introductions, increased 3.4 percent.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) ended the last trading day at $7.88. Company weekly volatility is calculated as 4.58% and price to cash ratio as 6.99. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) showed a weekly performance of 3.01%. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that its Chief Executive Officer, Dr. J. Joseph Kim, has been selected by The Aspen Institute to join its Health Innovators Fellowship. Dr. Kim, who co-founded Inovio, will work with a group of 20 healthcare leaders challenged to generate new solutions to improve healthcare treatments, access and delivery.

Leave a Reply

Your email address will not be published. Required fields are marked *